BioSpace News Archive

NanoVibronix, Inc. announced that the Centers for Medicare and Medicaid has assigned a unique, Level II product reimbursement code under the Healthcare Common Procedure Coding System for use in 2020.

Hoth Therapeutics, Inc. announced that its CEO and President, Robb Knie will be attending Benchmark’s 8thAnnual Discovery 1x1 Conference.

Post Hoc Analysis of Subset of Patients Treated in the Emergency Department Setting

As part of the continued expansion of the iReceptor Plus stakeholder’s community, a special partner meeting will be held in Haifa in parallel with the third SCAIR meeting

Today, 18th November 2019, RhoVac AB reports interim results from ongoing immunological studies at University of Tübingen, Germany concluding that treatment with RV001 can activate CD4+ T-cells and also CD8+ T-cells.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 VICTORIA study evaluating the efficacy and safety of vericiguat, a soluble guanylate cyclase (sGC) stimulator being developed to treat patients with worsening chronic heart failure, has met the primary efficacy endpoint.

Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis

Study data presented at AHA show Eko DUO combined with advanced artificial intelligence algorithm effectively identifies low ejection fraction in patients

Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment for OTL-200,

Ziopharm Oncology, Inc. (Nasdaq: ZIOP) today announced that the Company’s presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019, has been moved to 1:20 p.m. GMT (8:20 a.m. ET).